Business Context and Reporting Period
This Form 8-K is filed by Dynamics Special Purpose Corp. (DYNS) on May 24, 2022, reporting events occurring on May 19, 2022. The filing details Amendment No. 2 to the Business Combination Agreement between Dynamics, Explore Merger Sub, Inc., and Senti Biosciences, Inc. The amendment reflects a new financing arrangement with Bayer HealthCare LLC to support the proposed merger.
Key Financial Metrics and Transaction Details
- Financing Amount: $5,175,000 principal amount.
- Instrument: Unsecured, convertible promissory note issued by Senti Biosciences to Bayer HealthCare LLC.
- Interest Rate: 3.0% per annum.
- Maturity Date: 24 months from May 19, 2022.
- Conversion Terms: The note converts to Class A Common Stock of the combined company at a price of $10.00 per share upon the closing of the merger.
- Interest Treatment: All accrued interest is automatically cancelled and forgiven upon conversion at closing.
- Liquidity Impact: Proceeds count toward the minimum cash condition under the Business Combination Agreement as incremental equity financing.
Note: This filing does not provide standalone revenue, profit, cash flow, or margin data for Senti Biosciences or Dynamics Special Purpose Corp.
Material Changes
The primary material change is the execution of the Note Subscription Agreement and the issuance of the convertible note. This transaction amends the original Business Combination Agreement to incorporate the new financing structure. The filing does not report changes to historical financial performance metrics.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The financing is intended to facilitate the proposed merger. The combined company expects the note to convert into equity at closing, with the investor receiving registration rights equivalent to other PIPE financing participants.
Risks and Contingencies:
- Completion of the merger is contingent upon shareholder approval and satisfaction of closing conditions.
- Risks include the potential termination of the Business Combination Agreement, legal proceedings, and the impact of the COVID-19 pandemic.
- Uncertainty regarding the listing of Class A Common Stock on Nasdaq following the merger.
- Forward-looking statements regarding product development and clinical trials are subject to significant uncertainties.
Key Facts for Investor Verification
- Verify the final closing date of the merger to confirm the conversion of the $5,175,000 note into equity.
- Confirm that the $5,175,000 proceeds satisfy the minimum cash condition required in the Business Combination Agreement.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed risk factors and the full terms of the merger.
- Monitor shareholder voting results to ensure the merger is approved.
- Check for any subsequent amendments to the Note Subscription Agreement or Business Combination Agreement.